Metformin kilo kontrolünde yardımcı
Metformin as Treatment for Overweight
and Obese Adults: A Systematic Review
Kara M. Levri, MD, MPH1 Elizabeth Slaymaker, MD1,2 Allen Last, MD1 Julie Yeh, MD1 Jonathan Ference, PharmD1,3 Frank D’Amico, PhD1 Stephen A. Wilson, MD1
1University of Pittsburgh Medical Center St. Margaret, Pittsburgh, Pa 2Grace Medical Associates, Pittsburgh, Pa 3University of Oklahoma-Tulsa, Tulsa, Okla
ABSTRACT
PURPOSE We wanted to determine whether metformin is an effective medication
for treatment of overweight or obese adults who do not have diabetes mellitus or
polycystic ovary syndrome (PCOS).
METHODS We searched MEDLINE (1966–2003), EMBASE (1986–2003), Allied
and Complementary Medicine Database (1985-2003), International Pharmaceutical
Abstracts (1970-2003), the Cochrane Library, American College of Physicians
Journal Club, Database of Abstracts of Reviews of Effects, Cochrane Controlled
Trials Register, MEDLINE In-Process & Other Non-Indexed Citations, reference
lists of retrieved articles, and articles by selected authors and pharmaceutical
manufacturers. Inclusion criteria were being obese or overweight determined
by a BMI of 25 kg/m2 or greater or waist-to-hip ratio (WHR) of more than 0.8,
metformin use, and aged 18 years or older. Exclusion criteria were a diagnosis
of diabetes mellitus, polycystic ovarian syndrome or descriptors of polycystic
ovarian syndrome, human immunodefi ciency virus infection, and concomitant
antipsychotic medications. Trials were graded on an 11-point Jadad scale. Only
randomized controlled and blinded trials were accepted. Two reviewers independently
extracted data from each trial. Primary outcomes measured were changes
in BMI, WHR, and weight.
RESULTS Fifty-seven potentially relevant studies were initially identifi ed; 48 were
excluded because of lack of randomization, lack of blinding, failure to meet inclusion
or exclusion criteria, inaccessible outcomes, or improper study design. Nine
clinical trials met criteria for validity assessment. Four studies used the parameter
of waist-to-hip ratio, 3 studies included BMI, and 8 used weight. Two of the 9
studies showed a small reduction in WHR.
CONCLUSION Insuffi cient evidence exists for the use of metformin as treatment of
overweight or obese adults who do not have diabetes mellitus or polycystic ovary
syndrome. Further studies are needed to answer this clinical question.
Ann Fam Med 2005;3:457-461. DOI: 10.1370/afm.343.